Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated Split Virion Swine-Origin A/H1N1 Influenza Vaccine in Healthy European Adults and Elderly
2009-013344-37Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2009
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of Influenza A (H1N1) vaccine in Influenza A infection (2 arms), sponsored by Sanofi. Primary endpoints: Immunogenicity by hemagglutination inhibition (HAI) and Immunogenicity by seroneutralization (SN). Started Jul 2009; status: completed.
02
Drugs
Influenza A (H1N1) vaccine
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2009-013344-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013344-37.